Trial Design and Optimal Determination of CNS Activity of Small Molecule Targeted Therapy in NSCLC.

Authors :: Jennings EM
Camidge DR
Gadgeel S
Barker S
Source :: Clinical lung cancer [Clin Lung Cancer] 2024 Mar; Vol. 25 (2), pp. 91-99. Date of Electronic Publication: 2023 Dec 05.
Publication Year :: 2024
Abstract: Central nervous system (CNS) metastases are frequently diagnosed in patients with non-small cell lung cancer (NSCLC). Only recently, clinical trials are broadening eligibility to include patients with brain metastases, offering the potential for some assessment of CNS efficacy to be made. In this work we aim to review the available information on the activity of small molecule targeted drugs for advanced NSCLC with respect to CNS metastases. We analyze a framework for evaluation assessment regarding trials of systemic agents being conducted in patients with, or at risk from, CNS metastases, and provide examples of NSCLC targeted therapies evaluated in the CNS.<br /> (Copyright © 2023 Elsevier Inc. All rights reserved.)

Subjects :: Humans
Carcinoma, Non-Small-Cell Lung drug therapy
Carcinoma, Non-Small-Cell Lung pathology
Lung Neoplasms drug therapy
Lung Neoplasms pathology
Brain Neoplasms drug therapy
Brain Neoplasms secondary
Central Nervous System Neoplasms drug therapy
Central Nervous System Neoplasms secondary

Full Text Access

Tools